—
C+
C+ The full Closelook — membership. Open the C+ overview

Belite Bio Inc ADR (BLTE) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Belite Bio Inc ADR

BLTE in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Belite Bio is a clinical-stage biopharmaceutical company that develops treatments for diseases with few existing options. Its main candidate, an orally administered drug called Tinlarebant, is in a phase 3 trial meant to protect retinal tissue in patients with Stargardt disease type 1 and geographic atrophy. The company also has an earlier-stage oral therapy aimed at liver disease and related metabolic conditions still in preclinical work. It was founded in 2016, is based in San Diego, and operates as a subsidiary of a larger biosciences group.
Where it sits in the stack
Belite Bio sits outside Rubin, our index for the AI build-out; it belongs instead to the healthcare and biotechnology corner of our wider coverage universe, unconnected to any chip, data-centre or semiconductor sleeve.
Who it is priced against
Our peer-group data carries no fixed comparison set for this name. The market sometimes reads it alongside Apellis Pharmaceuticals, another developer working on treatments for geographic atrophy, as a rough point of reference.
Why Closelook tracks it
Belite Bio holds no seat in Rubin or any other Closelook index, and it does not yet carry a Closelook score; the diary has not quoted it in any edition to date.
What the diary watches
The diary watches for readouts from the phase 3 trial of Tinlarebant in Stargardt disease and geographic atrophy patients, since a trial result would reset the clinical picture.

Belite Bio Inc ADR (BLTE) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 27/100 composite (momentum 63, quality 5, valuation 8) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for BLTE, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 2 analyst actions on the wire · latest: price target by H.C. Wainwright, 2026-09-08

The Street on this name

Analyst actions and the latest print for BLTE from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target H.C. Wainwright — target 245 from 214 Target raised to $245 from $214 (+27.1% to spot) 2026-09-08
  • Price target Morgan Stanley — target 206 from 201 Target raised to $206 from $201 (+25.6% to spot) 2026-08-14

2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against BLTE on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What BLTE pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +9.8% in FY2025 39 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 66/100 · S&P 500 fund at 64, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-22
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.8% over 20 sessions. Factor regime → 2026-09-22
  • Sector × region Health care in US: +1.7% week · −2.3% month · +12.1% quarter · +12.6% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-22
  • Sovereign pressure Index -0.03 · down 0.40 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-22

FAQ · from the current data · as of 2026-09-23

Quick answers

What is Belite Bio Inc ADR (BLTE)?

Belite Bio Inc ADR trades as BLTE on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-23.

Is BLTE in a Closelook index?

Not currently — Belite Bio Inc ADR is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-23.

What is Belite Bio Inc ADR's Closelook composite score?

27 out of 100, with momentum 63, quality 5 and valuation 8 sub-scores, as of 2026-09-23. Scores are Closelook's own research readings, not ratings or investment advice.

Where does BLTE trade against its moving averages?

Uptrend stack intact: Trades +7.2% vs the 50-day and +9.4% vs the 200-day average, 12.3% below the 52-week high and +157.1% off the 52-week low; a golden cross printed 12 sessions ago. Computed from daily closes. As of 2026-09-22 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Belite Bio Inc ADR do?

Belite Bio is a clinical-stage biopharmaceutical company that develops treatments for diseases with few existing options. Its main candidate, an orally administered drug called Tinlarebant, is in a phase 3 trial meant to protect retinal tissue in patients with Stargardt disease type 1 and geographic atrophy. The company also has an earlier-stage oral therapy aimed at liver disease and related metabolic conditions still in preclinical work. Our peer-group data carries no fixed comparison set for this name. The market sometimes reads it alongside Apellis Pharmaceuticals, another developer working on treatments for geographic atrophy, as a rough point of reference.

Where does Belite Bio Inc ADR sit in the AI build-out?

Belite Bio sits outside Rubin, our index for the AI build-out; it belongs instead to the healthcare and biotechnology corner of our wider coverage universe, unconnected to any chip, data-centre or semiconductor sleeve. Belite Bio holds no seat in Rubin or any other Closelook index, and it does not yet carry a Closelook score; the diary has not quoted it in any edition to date.

Does Belite Bio Inc ADR pay a dividend?

No cash distribution shows in Belite Bio Inc ADR’s price series over the last three years. The share count rose 9.8% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Belite Bio Inc ADR recently?

The most recent analyst action on Belite Bio Inc ADR on the Closelook wire is a price target by H.C. Wainwright on 2026-09-08 (target 245 from 214). 2 actions on the analyst wire since 2026-08-13: 2 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for BLTE, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.